These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 11852620

  • 1. Dyslipidaemia in diabetes--a GP guide.
    Barnett AH.
    Practitioner; 2002 Feb; 246(1631):120-3. PubMed ID: 11852620
    [No Abstract] [Full Text] [Related]

  • 2. Fenofibrate set to benefit from new research on its active metabolite, fenofibric acid.
    Cardiovasc J Afr; 2008 Feb; 19(3):171-2. PubMed ID: 18568186
    [No Abstract] [Full Text] [Related]

  • 3. [Favorable effects of decreasing lipids in patients with diabetes mellitus].
    Gouni-Berthold I, Krone W.
    Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S252-4. PubMed ID: 17139581
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Lipid-lowering cardiovascular prevention in type 2-diabetes. Statins are effective according to the FIELD study].
    Båvenholm P, Attvall S, Nilsson PM.
    Lakartidningen; 2006 Dec; 103(35):2462-6. PubMed ID: 17002161
    [No Abstract] [Full Text] [Related]

  • 7. The 2003 Canadian recommendations for dyslipidemia management: revisions are needed.
    Manuel DG, Tanuseputro P, Mustard CA, Schultz SE, Anderson GM, Ardal S, Alter DA, Laupacis A.
    CMAJ; 2005 Apr 12; 172(8):1027-31. PubMed ID: 15824409
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
    Staels B, Maes M, Zambon A.
    Nat Clin Pract Cardiovasc Med; 2008 Sep 12; 5(9):542-53. PubMed ID: 18628776
    [Abstract] [Full Text] [Related]

  • 14. The metabolic syndrome: targeting dyslipidaemia to reduce coronary risk.
    Ginsberg HN, Stalenhoef AF.
    J Cardiovasc Risk; 2003 Apr 12; 10(2):121-8. PubMed ID: 12668909
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Interpreting clinical trials of diabetic dyslipidaemia: new insights.
    Wierzbicki AS.
    Diabetes Obes Metab; 2009 Mar 12; 11(3):261-70. PubMed ID: 17645560
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Elevated remnant-like particle cholesterol concentration: a characteristic feature of the atherogenic lipoprotein phenotype.
    Twickler TB, Dallinga-Thie GM, Cohn JS, Chapman MJ.
    Circulation; 2004 Apr 27; 109(16):1918-25. PubMed ID: 15117861
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.